Skip to main content Help with accessibility Skip to main navigation



Chronic kidney disease (NICE TA775)

NICE TA775 - Dapagliflozin for treating chronic kidney disease

Amber level 0


Nice TA:


Commissioning responsibility:


PbR excluded:


BNF chapter:
Endocrine system


1.1 Dapagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults. It is recommended only if:

  • it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and

  • people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:

    • have type 2 diabetes or

    • have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more.


LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
What do the colours mean?

Last Updated: 19 - Apr - 2022